中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
12期
1508-1509
,共2页
肺疾病,慢性阻塞性,稳定期%匹多莫德%免疫
肺疾病,慢性阻塞性,穩定期%匹多莫德%免疫
폐질병,만성조새성,은정기%필다막덕%면역
Pulmonary disease,chronic obstructive,stable%Pidotimod%Immune
目的 观察应用匹多莫德辅助治疗慢性阻塞性肺疾病稳定期患者的临床疗效.方法 93例慢性阻塞性肺疾病稳定期患者完全随机分为观察组(47例)与对照组(46例).对照组给予支气管扩张剂、呼吸肌锻炼、氧疗、营养及对症支持等治疗.观察组在对照组基础上给予匹多莫德分散片0.8g/次,口服,1次/d.疗程均为8周.2组治疗前后均测定生活质量评分及慢性阻塞性肺疾病急性加重发作例数、住院治疗例数及住院时间,并进行比较.结果 治疗后6个月,与对照组比较,观察组生活质量评分、慢性阻塞性肺疾病急性加重发作发生率、慢性阻塞性肺疾病急性加重需住院治疗发生率及住院时间均明显减少[分别为(41.2±2.2)分比(49.3±2.1)分,28.3％ (13/46)比84.4％(38/45),15.2％ (7/46)比57.8％(26/45),(8.0±0.3)d比(14.0±0.4)d,均P＜0.05].结论 匹多莫德能有效提高患者机体免疫力,对减少慢性阻塞性肺疾病稳定期患者急性加重的发作有确切效果.
目的 觀察應用匹多莫德輔助治療慢性阻塞性肺疾病穩定期患者的臨床療效.方法 93例慢性阻塞性肺疾病穩定期患者完全隨機分為觀察組(47例)與對照組(46例).對照組給予支氣管擴張劑、呼吸肌鍛煉、氧療、營養及對癥支持等治療.觀察組在對照組基礎上給予匹多莫德分散片0.8g/次,口服,1次/d.療程均為8週.2組治療前後均測定生活質量評分及慢性阻塞性肺疾病急性加重髮作例數、住院治療例數及住院時間,併進行比較.結果 治療後6箇月,與對照組比較,觀察組生活質量評分、慢性阻塞性肺疾病急性加重髮作髮生率、慢性阻塞性肺疾病急性加重需住院治療髮生率及住院時間均明顯減少[分彆為(41.2±2.2)分比(49.3±2.1)分,28.3％ (13/46)比84.4％(38/45),15.2％ (7/46)比57.8％(26/45),(8.0±0.3)d比(14.0±0.4)d,均P＜0.05].結論 匹多莫德能有效提高患者機體免疫力,對減少慢性阻塞性肺疾病穩定期患者急性加重的髮作有確切效果.
목적 관찰응용필다막덕보조치료만성조새성폐질병은정기환자적림상료효.방법 93례만성조새성폐질병은정기환자완전수궤분위관찰조(47례)여대조조(46례).대조조급여지기관확장제、호흡기단련、양료、영양급대증지지등치료.관찰조재대조조기출상급여필다막덕분산편0.8g/차,구복,1차/d.료정균위8주.2조치료전후균측정생활질량평분급만성조새성폐질병급성가중발작례수、주원치료례수급주원시간,병진행비교.결과 치료후6개월,여대조조비교,관찰조생활질량평분、만성조새성폐질병급성가중발작발생솔、만성조새성폐질병급성가중수주원치료발생솔급주원시간균명현감소[분별위(41.2±2.2)분비(49.3±2.1)분,28.3％ (13/46)비84.4％(38/45),15.2％ (7/46)비57.8％(26/45),(8.0±0.3)d비(14.0±0.4)d,균P＜0.05].결론 필다막덕능유효제고환자궤체면역력,대감소만성조새성폐질병은정기환자급성가중적발작유학절효과.
Objective To observe the clinical curative effect of pidotimod on stable chronic obstructive pulmonary disease.Methods All 93 cases of stable chronic obstructive pulmonary disease patients were randomly divided into observation group(47 cases)and control group (46 cases).The patients in control group were given bronchial diastolic agent,muscle training,nutrition support,family oxygen and symptomatic treatment.The patients in observation group were given pidotimod.Treatment lasted for eight weeks.Clinical symptom scores before and after treatment and chronic obstructive pulmonary disease in acute exacerbation period (AECOPD) cases were assayed.Results Six months after treatment,the StGeorg's respiration questionnaire scores,AECOPD attack rate,incidence and days of AECOPD in hospital in observation group were statistically less than those in control group [(41.2 ±2.2) scores vs (49.3 ± 2.1) scores,28.3％ (13/46) vs 84.4％ (38/45),15.2％ (7/46) vs 57.8％(26/45),(8.0 ± 0.3) d vs (14.0 ± 0.4) d,respectively,all P ＜ 0.05].Conclusions Pidotimod can effectively enhance the immunity of the patients and reduce the cases of AECOPD in stable chronic obstructive pulmonary disease patients.
